Summary: Researchers have revealed the 3D structure of NMDA receptor molecules that are critical for brain health. NMDA receptors are believed to contribute to a range of neurological and psychiatric disorders, including schizophrenia, depression, stroke, and Alzheimer’s disease. The new model could help with the development of novel treatments for neuropsychiatric disorders.
New images from scientists at Cold Spring Harbor Laboratory (CSHL) reveal for the first time the three-dimensional structures of a set of molecules critical for healthy brain function. The molecules are members of a family of proteins in the brain known as NMDA receptors, which mediate the passage of essential signals between neurons.
The detailed pictures generated by the CSHL team will serve as a valuable blueprint for drug developers working on new treatments for schizophrenia, depression, and other neuropsychiatric conditions.
“This NMDA receptor is such an important drug target,” says Tsung-Han Chou, a postdoctoral researcher in CSHL Professor Hiro Furukawa’s lab. That’s because dysfunctional NMDA receptors are thought to contribute to a wide range of conditions, including not just depression and schizophrenia, but also Alzheimer’s disease, stroke, and seizures.
“We hope our images, which visualize the receptor for the first time, will facilitate drug development across the field based on our structural information,” Chou says.
NMDA receptors are found on neurons throughout the brain. When activated by a signaling molecule known as glutamate—one of the brain’s many neurotransmitters—the receptor changes shape, opening a channel into the cell. This increases the likelihood that the neurons will fire off a signal to neighboring cells.
Communication between neurons is critical for everything from movement to memory. Dysfunction and disease can result when NMDA receptors cause either too much neural communication or too little.
“GluN1-2C, GluN1-2A-2C, and GluN1-2D NMDA receptors exist in discrete brain regions, such as the cerebellum, at a defined period during brain development,” Furukawa explains.
“It is hypothesized that abnormally low-functioning NMDA receptors containing GluN1-2C cause schizophrenia-like symptoms.”
While some NMDA receptors’ structures are better studied, less was known about those that Furukawa’s team focused on in their new study. A more complete picture was needed because the ability to target specific types of NMDA receptors would give pharmaceutical developers greater control over where in the brain a potential drug will be active.
And when it comes to developing better therapies, Chou says, “the more information we can get, the better.”
Furukawa, Chou, and their colleagues used a method called cryo-electron microscopy to capture a series of images of the receptors, which reveal their shapes in exquisite detail. Some images show the receptors grasping glutamate, the natural neurotransmitter that switches them on; others show the receptors activated by a molecule used in the lab to enhance NMDA signaling.
By revealing exactly where and how those molecules interact, the new pictures will help guide the design of potential therapies that switch off overactive NMDA receptors or turn on those that aren’t active enough.
About this neuroscience research news
Author: Samuel Diamond
Contact: Samuel Diamond – CSHL
Image: The image is credited to Furukawa Lab
Original Research: Closed access.
“Structural insights into assembly and function of GluN1-2C, GluN1-2A-2C, and GluN1-2D NMDARs” by Hiro Furukawa et al. Molecular Cell
Structural insights into assembly and function of GluN1-2C, GluN1-2A-2C, and GluN1-2D NMDARs
Neurotransmission mediated by diverse subtypes of N-methyl-D-aspartate receptors (NMDARs) is fundamental for basic brain functions and development as well as neuropsychiatric diseases and disorders. NMDARs are glycine- and glutamate-gated ion channels that exist as heterotetramers composed of obligatory GluN1 and GluN2(A-D) and/or GluN3(A-B). The GluN2C and GluN2D subunits form ion channels with distinct properties and spatio-temporal expression patterns.
Here, we provide the structures of the agonist-bound human GluN1-2C NMDAR in the presence and absence of the GluN2C-selective positive allosteric potentiator (PAM), PYD-106, the agonist-bound GluN1-2A-2C tri-heteromeric NMDAR, and agonist-bound GluN1-2D NMDARs by single-particle electron cryomicroscopy.
Our analysis shows unique inter-subunit and domain arrangements of the GluN2C NMDARs, which contribute to functional regulation and formation of the PAM binding pocket and is distinct from GluN2D NMDARs.
Our findings here provide the fundamental blueprint to study GluN2C- and GluN2D-containing NMDARs, which are uniquely involved in neuropsychiatric disorders.